These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
34. Reduction of interleukin 8 and platelet-derived growth factor levels by topical ketorolac, 0.45%, in patients with diabetic retinopathy. Schoenberger SD, Kim SJ, Shah R, Sheng J, Cherney E. JAMA Ophthalmol; 2014 Jan 01; 132(1):32-7. PubMed ID: 24336915 [Abstract] [Full Text] [Related]
35. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. Lane SS, Modi SS, Lehmann RP, Holland EJ. J Cataract Refract Surg; 2007 Jan 01; 33(1):53-8. PubMed ID: 17189793 [Abstract] [Full Text] [Related]
36. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Waterbury LD, Silliman D, Jolas T. Curr Med Res Opin; 2006 Jun 01; 22(6):1133-40. PubMed ID: 16846546 [Abstract] [Full Text] [Related]
37. Effect of preoperative use of topical prednisolone acetate, ketorolac tromethamine, nepafenac and placebo, on the maintenance of intraoperative mydriasis during cataract surgery: a randomized trial. Zanetti FR, Fulco EA, Chaves FR, da Costa Pinto AP, Arieta CE, Lira RP. Indian J Ophthalmol; 2012 Jul 01; 60(4):277-81. PubMed ID: 22824596 [Abstract] [Full Text] [Related]